Share on LinkedInShare on LinkedIn

ARTICLE · 24 NOVEMBER 2017

Federal Circuit Clarifies Probative Value Of Patent Dance Statements

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

The United States Court of Appeals for the Federal Circuit ("Federal Circuit") considered the Biologics Price Competition and Innovation Act ("BPCAI") once again on November 13, 2017.

United StatesIntellectual Property

In short

The Situation: The Biologics Price Competition and Innovation Act was considered in a November 2017 decision by the United States Court of Appeals for the Federal Circuit.

The Result: The court found that the commercial marketing of Apotex's proposed biosimilar versions of Amgen's Neulasta® and Neupogen® would not infringe on a patent held by Amgen.

Looking Ahead: Amgen v. Apotex underscores the importance of fact witness testimony and other factual evidence to support arguments regarding infringement.


The United States Court of Appeals for the Federal Circuit ("Federal Circuit") considered the Biologics Price Competition and Innovation Act ("BPCAI") once again on November 13, 2017. The Federal Circuit issued a nonprecedential decision in Amgen v. Apotex, on appeal from the United States District Court for the Southern District of Florida, finding that the commercial marketing of Apotex's proposed biosimilar versions of Amgen's Neulasta® and

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from